15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02481453 (ClinicalTrials.gov) | July 15, 2015 | 13/5/2015 | Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis | Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI | Inclusion Body Myositis (IBM) | Drug: Rapamycin;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 45 Years | 85 Years | All | 44 | Phase 2/Phase 3 | France |